This demonstrates a new theoretical concept for a triple-action DDS to be generated, which includes: (i) passive targeting using nanosized MSNs as carriers (MCM-41 species); (ii) active targeting by employing TAM as a targeting vector to selectively bind to ER-overexpressing breast tumours; and (iii) pH-controlled drug release by grafting the polymer PLH onto the surface of MSNs to act as a pH-sensitive gatekeeper and prevent premature drug leakage. This evidence concerns the gene ESR1 and breast neoplasm.